MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options and Restricted Stock Units
ROCKVILLE, MD, June 14, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 11 June 2024, a total of 325,608 options ("Option Grants") in respect of common stock in the Company ("Common Stock"), and 170,936 restricted stock units ("RSU"s) were granted to PDMRs who are non-executive directors of the Company. These Options Grants and RSUs were made pursuant to the Company's Equity Grant Policy for non-executive directors.
Details of the Option Grants are given below:
| Option Grants to PDMRs | |
| Al-Wakeel, Yasir | 40,701 |
| Brooke, Will | 40,701 |
| Balthrop, Patrick | 40,701 |
| Douglas, Richard | 40,701 |
| Erck, Stanley | 40,701 |
| Hemrajani, Rekha | 40,701 |
| Johnston, John | 40,701 |
| Mandell, Art | 40,701 |
| Total | 325,608 |
Option Grants for non-executive directors fully vest at the end of twelve (12) months after date of grant. (1 year cliff until fully vested).
The Options Grants have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 11 June 2024, of $4.68 on the United States Nasdaq Stock Exchange.
Details of the RSUs are given below:
| Option Grants to PDMRs | |
| Al-Wakeel, Yasir | 21,367 |
| Brooke, Will | 21,367 |
| Balthrop, Patrick | 21,367 |
| Douglas, Richard | 21,367 |
| Erck, Stanley | 21,367 |
| Hemrajani, Rekha | 21,367 |
| Johnston, John | 21,367 |
| Mandell, Art | 21,367 |
| Total | 170,936 |
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400
|
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| a) Yasir Al-Wakeel b) Will Brooke c) Patrick Balthrop d) Richard Douglas e) Stanley Erck f) Rekha Hemrajani g) John Johnston h) Art Mandell | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| a) Non-Executive Director b) Non-Executive Director c) Non-Executive Director d) Non-Executive Chairman e) Non-Executive Director f) Non-Executive Director g) Non-Executive Director h) Non-Executive Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| MaxCyte Inc. | |||
| b)
| LEI
| 54930053YHXULRFCU991 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| | | ||||
| Identification code | US57777K1060 | ||||
| | | ||||
| b)
| Nature of the transaction
| Grant of options of common stock | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Exercise Price(s) | Volume(s) | | |
| | | a) $4.68 | 40,701 | | |
| | | b) $4.68 | 40,701 | | |
| | | c) $4.68 | 40,701 | | |
| | | d) $4.68 | 40,701 | | |
| | | e) $4.68 | 40,701 | | |
| | | f) $4.68 | 40,701 | | |
| | | g) $4.68 | 40,701 | | |
| | | h) $4.68 | 40,701 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 325,608 | ||||
| | | ||||
| - Price | $4.68 | ||||
| | | ||||
| e)
| Date of the transaction
| 11 June 2024 | |||
| f)
| Place of the transaction
| US Stock Exchange, Nasdaq | |||
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| a) Yasir Al-Wakeel b) Will Brooke c) Patrick Balthrop d) Richard Douglas e) Stanley Erck f) Rekha Hemrajani g) John Johnston h) Art Mandell | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| a) Non-Executive Director b) Non-Executive Director c) Non-Executive Director d) Non-Executive Chairman e) Non-Executive Director f) Non-Executive Director g) Non-Executive Director h) Non-Executive Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| MaxCyte Inc. | |||
| b)
| LEI
| 54930053YHXULRFCU991 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| | | ||||
| Identification code | US57777K1060 | ||||
| | | ||||
| b)
| Nature of the transaction
| Grant of restricted stock units | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Exercise Price(s) | Volume(s) | | |
| | | i) N/A | 40,701 | | |
| | | j) N/A | 40,701 | | |
| | | k) N/A | 40,701 | | |
| | | l) N/A | 40,701 | | |
| | | m) N/A | 40,701 | | |
| | | n) N/A | 40,701 | | |
| | | o) N/A | 40,701 | | |
| | | p) N/A | 40,701 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 170,936 | ||||
| | | ||||
| - Price | No exercise price for the RSUs | ||||
| | | ||||
| e)
| Date of the transaction
| 11 June 2024 | |||
| f)
| Place of the transaction
| US Stock Exchange, Nasdaq | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.